Testing AC-101 tablets in adults with moderately to severely active ulcerative colitis

Trial details

Who runs it

Accro Bioscience (Suzhou) Limited

Trial code

NCT07755241

Record updated

28 October 2026

Original description

This is a Phase Ⅱb, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-finding study of AC-101 tablets in patients with moderately to severely active ulcerative colitis (UC). The study will evaluate the efficacy, safety, and pharmacokinetics of AC-101 compared with placebo in patients who have had an inadequate response, loss of response, or intolerance to prior advanced therapies or to prior conventional therapies. The study consists of a screening period (up to 4 weeks), a 12-week induction period, a 40-week extension period, and a 4-week safety follow-up period.Read full original descriptionShow less

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-finding Study to Evaluate the Efficacy and Safety of AC-101 Tablets in Patients With Moderately to Severely Active Ulcerative Colitis

This is a Phase Ⅱb, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-finding study of AC-101 tablets in patients with moderately to severely active ulcerative colitis (UC). The study will evaluate the efficacy, safety, and pharmacokinetics of AC-101 compared with placebo in patients who have had an inadequate response, loss of response, or intolerance to prior advanced therapies or to prior conventional therapies. The study consists of a screening period (up to 4 weeks), a 12-week induction period, a 40-week extension period, and a 4-week safety follow-up period.

Inclusion: Male or female participants aged ≥ 18 and ≤ 75 years；; Must sign the Informed Consent Form and be willing to participate in the study; Diagnosis of UC confirmed at least 3 months prior to screening, supported by both endoscopic and histological evidence; Evidence of UC extending ≥ 15 cm from the anal verge as assessed by colonoscopy. Moderately to severely active UC, defined as a modified Mayo Score of 5 to 9, with an Endoscopic Subscore ≥ 2; Documented failure to prior advanced therapies or prior conventional therapies; Female participants must meet either criterion a) or b), and male participants must meet criterion c) to be eligible for enrollment:; Female participants of non-childbearing potential; Female participants of childbearing potential who are not pregnant must agree to use highly effective contraception during the treatment period and for at least 1 month after the last dose of study treatment; Male participants with a pregnant or non-pregnant female partner of childbearing potential must agree to use contraception during the treatment period and for at least 1 month after the last dose of study treatment.

Exclusion: Hospitalization for exacerbation of UC within 12 weeks prior to screening; Adenomatous colonic polyps that have not been removed prior to study enrollment; History of current or prior serious opportunistic infection; Syphilis, or positive syphilis-specific antibody test at screening; Treatment with advanced therapies for UC within 8 weeks or 5 half-lives prior to randomization; Treatment with intravenous corticosteroids within 2 weeks prior to randomization; Treatment with intravenous immunoglobulins or plasmapheresis within 12 weeks prior to randomization; Vaccination with live attenuated vaccines within 4 weeks prior to randomization, or a plan to receive such vaccines during the study period; History of myocardial infarction, acute stroke, transient ischemic attack, thromboembolic events, clinically significant arrhythmia, unstable angina, coronary artery bypass grafting, or severe pulmonary heart disease/pulmonary hypertension within 3 months prior to randomization, which, in the investigator's judgment, may affect the evaluation of study results; History of gastrointestinal dysplasia, or presence of dysplasia detected in any biopsy performed during the screening colonoscopy; Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease, or clinical findings suggestive of Crohn's disease; Presence of an ostomy or fistula; Risk of tuberculosis ; Presence of active or chronic recurrent infection; Patients with any of the following hepatitis B screening results:; Acute or chronic hepatitis B infection; or Positive hepatitis B virus (HBV) test at screening (HBsAg positive); or HBsAg negative, hepatitis B core antibody (HBcAb) positive, with detectable HBV-DNA; Current hepatitis C infection, or positive hepatitis C virus (HCV) test at screening; Human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome , or positive HIV antibody test at screening; History of fecal microbiota transplantation; Presence of any other unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurological/psychiatric, or other medical condition that, in the investigator's judgment, may interfere with the study results; Known history of immunodeficiency; other acquired or congenital immunodeficiency disorders; or history of organ transplantation; History of malignancy within 5 years prior to screening, with the exception of adequately treated carcinoma in situ of the cervix, or basal cell or squamous cell carcinoma of the skin; Any other condition that, in the investigator's opinion, may affect the patient's safety or compliance, or preclude the patient from completing the study; Treatment with leukocyte apheresis within 12 weeks prior to randomization; Treatment with lymphocyte-depleting therapy; Female patients who are pregnant, lactating, or have a positive serum pregnancy test at screening; Severe extensive colitis; Positive stool pathogen test or positive test for Clostridioides difficile toxin at screening; Requirement for parenteral nutrition.

ClinicalTrials.gov NCT07755241